World premiere - myriamed and SYNENTEC present the myrImager at the ISSCR Annual Meeting in Hamburg

After extensive development and beta testing, we are pleased to present the myrImager system from myriamed and SYNENTEC - a groundbreaking platform solution for tissue culture and drug development.

To this end, myriamed GmbH from Göttingen and SYNENTEC GmbH from Elmshorn near Hamburg have entered into a partnership for the development and distribution of the myrImager.

The myrImager is a video-optical analysis device that was developed in parallel with the myrPlates and adapted to them. In combination with the myriamed 48-well 3D cell/tissue culture plates, the myrPlates, the myrImager system offers a comprehensive macroscopic imaging solution for the use of artificial tissue models in research and drug screening in the development of new medicines.

The myrImager was developed by myriamed GmbH and transferred into a market-ready version with the help of SYNENTEC GmbH in order to make the optical recording and analysis of tissue structures cultivated on the myrPlates accessible to a wide range of customers and users. The device can be used for high-output screening and is specially designed for use with the myrPlates.

With this cooperation, myriamed GmbH now offers a complete platform technology for drug screening and the development of disease models, which, in addition to greater efficiency and accuracy, also offers the possibility of working with fewer animal experiments in drug development in the future.

SYNENTEC describes the cooperation with myriamed as follows: "Our 20 years of experience in the development of automated cell imaging microscopes enables us to optimally capture the specific requirements of our customers in the pharmaceutical and biotech sectors. The cooperation with myriamed therefore seemed extremely sensible and obvious to us, as our automated cell imaging microscopes already cover the imaging market worldwide and we can now perfectly complement the 3D stem cell area with the myrImager, especially in the macroscopic area for the detection and analysis of myrPlates. We are delighted to have made this new screening platform possible together with the excellent team at myriamed."

The 3D tissue models obtained with the myriamed technology based on iPS cells are significantly closer to humans than many animal models and, with the myrIamger, provide comprehensive insights into the functionality and regenerative capacity of muscle cells.

Dr. Tim Meyer from the University Medical Center Göttingen, as co-developer and user, explains that: "the combination of artificial tissues, myrPlates and the myrImager allows for the first time a simple and reproducible use of artificial heart tissues in pharmacological and toxicological screens."

Mr. Meyer and Mr. Budde received the Animal Welfare Research Award in 2022 for the utilization of the myrImager in automated high-throughput screens.

Developer Tim Meyer emphasizes: "Our platform of myrImager, the myrPlates and our fabric structures offers simple and safe use for our customers." "Thanks to the non-contact and parallel measurement, values such as force or beat frequency of the muscle cells in the myrPlates can also be measured and evaluated over longer periods of time."

As the world's leading event for stem cell research and regenerative medicine, ISSCR 2024 in Hamburg provides the perfect setting for the market launch of the myrImager and the cooperation between myriamed and SYNENTEC.

More than 4000 scientists from all over the world will have the opportunity to experience the myrImager live and exchange ideas with representatives from myriamed and SYNENTEC.

Please meet myriamed at exhibition booth 615 at ISSCR 2024 July 10th - July 13th, 2024, in Hamburg Germany.

The myrTeam will be delighted to introduce you to our broad all human product portfolio and drug discovery services:

-myrDisease: broad portfolio of induced pluripotent stem cell-derived disease models, including CRISPR-engineered models
-myrCells: induced pluripotent stem cell derived cardiomyocytes, skeletal muscle cells, and fibroblasts
-myrTissue: tissue engineered heart muscle, skeletal muscle, and connective tissue as well as brain organoids from myrCells
-myrPlates: 48-well culture plates for standardized production and culture of heart muscle, skeletal muscle and connective tissue
-myrImager (new): high-content imager for advanced myrPlate screens
-myrServices: fee-for-service and risk sharing program to accelerate drug development in patient-in-the dish models

About myriamed GmbH:

Based in Göttingen, myriamed GmbH was founded in 2012 as a spin-off of the University Medical Center Göttingen to exploit innovative cell and tissue models for drug discovery and supports customers such as drug developers with best-in-class cell and tissue models. For example, myriamed integrates unique, patented cell (myrCell) and tissue models for heart, skeleton, brain and connective tissue (myrTissue) into versatile disease modeling platforms (myrDisease) to enable high-throughput, high-content phenotypic screens (myrScreen) in powerful patient-in-the-dish models.

At myriamed, we are convinced that the next generation of drugs with predictable safety and efficacy profiles will be discovered and developed in human disease models. With its world-class expertise and range of breakthrough cell and tissue technologies, myriamed strives to be a first-class partner for ambitious drug developers.

myriamed has been distributing myrPlates since 2020 and we have partnered with SYNENTEC in response to multiple customer requests to offer a user-friendly end-user device

www.myriamed.com

About SYNENTEC:

SYNENTEC GmbH is a company that specializes in the development, production and distribution of product solutions in the life sciences sector. The portfolio includes automated cell culture microscopes, an associated software ecosystem and lab automation solutions, which are developed and produced in Elmshorn. The products are used worldwide in the biotechnology and pharmaceutical industries as well as in academic and industrial research. The company was founded in 2005 and now employs an interdisciplinary team of engineers, software developers, biologists, technicians and many helping hands with locations in Elmshorn, Kiel, Bochum, Lübeck and Hasewinkel.

myrPlate and myrImager publications:

Meyer T, Tiburcy M, Zimmermann WH (2019) Engineered Heart Tissue-on-Plate Models for Phenotypic Drug Screens. Adv Drug Deliv Rev 140:93-100

Tiburcy M, Meyer T, Liaw NY, Zimmermann WH (2020) Generation of Engineered Human Myocardium in a Multi-well Format. STAR Protoc. 1:100032.

Santos GL, DeGrave AN, Rehman A, Al Disi S, Xhaxho K, Schröder H, Bao G, Meyer T, Tiburcy M, Dworatzek E, Zimmermann WH, Lutz S (2022) Using different geometries to modulate the cardiac fibroblast phenotype and the biomechanical properties of engineered connective tissues. Biomater Adv. 139:213041.

Seibertz F, Rubio T, Springer R, Popp F, Ritter M, Liutkute A, Bartelt L, Stelzer L, Haghighi F, Pietras J, Windel H, Díaz I Pedrosa N, Rapedius M, Döring Y, Solano R, Hindmarsh R, Shi R, Tiburcy M, Brügmann T, Kutschka I, Streckfuss-Bömeke K, Kensah G, Cyganek L, Zimmermann WH, Voigt N (2023) Atrial fibrillation-associated electrical remodeling in human induced pluripotent stem cell-derived atrial cardiomyocytes: a novel pathway for antiarrhythmic therapy development. Cardiovasc Res. 119:2623-2637.

Kyriakopoulou E, Versteeg D, de Ruiter H, Perini I, Seibertz F, Döring Y, Zentilin L, Tsui H, van Kampen SJ, Tiburcy M, Meyer T, Voigt N, The Netherlands ACM Registry, van Tintelen JP, Zimmermann WH, Giacca M, van Rooij E (2023) Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat Cardiovasc Res 2:1262-1276

Shahriyari M, Rinn M, Hofemeier AD, Babych A, Zimmermann WH, Tiburcy M (2023) Protocol to develop force-generating human skeletal muscle organoids. STAR Protoc. 5(1):102794.

myriamed GmbH
Rudolf-Wissell-Straße 28a
37079 Göttingen
Germany

https://www.myriamed.com

Herr Dr.Timm Eifler
+4955128878170
+4955128878171
contact@myriamed.com

About myriamed GmbH:
myriamed GmbH, based in Göttingen, was founded in 2012 as a spin-off of the University Medical Center Göttingen to exploit innovative cell and tissue models for drug discovery. myriamed integrates unique, patented cell (myrCell) and tissue models for heart, skeleton, brain and connective tissue (myrTissue) into versatile disease modeling platforms (myrDisease) to enable high-throughput, high-content phenotypic screens (myrScreen) in powerful patient-in-the-dish models. At myriamed, we are convinced that the next generation of drugs with predictable safety and efficacy profiles will be discovered and developed in human disease models. With its world-class expertise and range of breakthrough cell and tissue technologies, myriamed strives to be a premier partner for ambitious drug developers. www.myriamed.com

This release was published on openPR.